Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund trimmed its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 29.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 210,162 shares of the medical research company’s stock after selling 86,213 shares during the quarter. New York State Common Retirement Fund’s holdings in Exact Sciences were worth $11,809,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after acquiring an additional 7,873 shares during the last quarter. Champlain Investment Partners LLC boosted its position in shares of Exact Sciences by 10.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock valued at $169,924,000 after purchasing an additional 245,980 shares during the period. Bellevue Group AG increased its stake in Exact Sciences by 25.1% in the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock worth $98,738,000 after purchasing an additional 290,585 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock worth $88,017,000 after buying an additional 45,015 shares during the period. Finally, Groupama Asset Managment purchased a new stake in Exact Sciences during the third quarter valued at about $821,000. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Up 4.1 %

Shares of NASDAQ EXAS opened at $51.28 on Tuesday. The business has a 50 day simple moving average of $54.72 and a 200 day simple moving average of $60.00. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62. The stock has a market cap of $9.53 billion, a price-to-earnings ratio of -9.21 and a beta of 1.24. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. On average, research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on EXAS shares. Sanford C. Bernstein lifted their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Piper Sandler cut their target price on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Scotiabank raised their target price on Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research report on Monday. Finally, Stifel Nicolaus dropped their price target on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $72.24.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.